EP Patent

EP4680276A1 — Immunogenic compositions and uses thereof

Assigned to Flagship Pioneering Innovations VI Inc · Expires 2026-01-21 · 0y expired

What this patent protects

The present disclosure features compositions including polyribonucleotides having one or more expression augmenting elements or spacer elements. The polyribonucleotides described herein may increase the stability of the polyribonucleotide and/or may increase the expression of a p…

USPTO Abstract

The present disclosure features compositions including polyribonucleotides having one or more expression augmenting elements or spacer elements. The polyribonucleotides described herein may increase the stability of the polyribonucleotide and/or may increase the expression of a polynucleotide cargo encoded by the polyribonucleotide.

Drugs covered by this patent

Patent Metadata

Patent number
EP4680276A1
Jurisdiction
EP
Classification
—
Expires
2026-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Flagship Pioneering Innovations VI Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.